Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain

Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain

<h4>Background/Objective</h4> AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in less bleeding, fewer hospi...

Full description

Bibliographic Details
Main Authors: Simone Rivolo, Manuela Di Fusco, Carlos Polanco, Amiee Kang, Devender Dhanda, Mirko Savone, Aristeidis Skandamis, Thitima Kongnakorn, Javier Soto
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589164/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589164/?tool=EBI

Similar Items